Payment overview · 2025
General Payments
$817.33
52 reported records · 20 companies
Healthcare provider profile · identity verified
Michael A Geile, MD
Allopathic & Osteopathic Physicians|Internal Medicine · RICHMOND, KY · NPI 1861499022
Verified facts
What the public records show
CMS Open Payments records show Michael A Geile, MD received $817.33 in general payments during 2025 across 52 reported records.
Lilly USA, LLC accounted for 20.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 126 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 102 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Trelegy Ellipta by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 102 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $167.24 | 20.5% | 8 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $145.66 | 17.8% | 14 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $48.75 | 6.0% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $47.98 | 5.9% | 2 | 2025 |
| Dynavax Technologies Corporation | Unresolved — no canonical attribution shown | $45.27 | 5.5% | 3 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $44.83 | 5.5% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $44.42 | 5.4% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $31.56 | 3.9% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $30.72 | 3.8% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $29.69 | 3.6% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $29.29 | 3.6% | 2 | 2025 |
| CSL Behring | Unresolved — no canonical attribution shown | $25.58 | 3.1% | 1 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $18.72 | 2.3% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $18.24 | 2.2% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $15.71 | 1.9% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $15.46 | 1.9% | 1 | 2025 |
| EVOKE PHARMA, INC. | Unresolved — no canonical attribution shown | $15.02 | 1.8% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$14.72 | 1.8% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.44 | 1.8% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $14.03 | 1.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $817.33 | 52 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $147.36 | 7 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $93.01 | 10 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $52.65 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $51.44 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $48.75 | 3 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $47.98 | 2 | 2025 |
Source payment records
|
|||||
| Heplisav-B Normalized: heplisav b |
Drug | Dynavax Technologies Corporation | $45.27 | 3 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $44.83 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $44.42 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $32.68 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $30.72 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $30.72 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $29.69 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $29.29 | 2 | 2025 |
Source payment records
|
|||||
| Haegarda Normalized: haegarda |
Biological | CSL Behring | $25.58 | 1 | 2025 |
Source payment records
|
|||||
| EVKEEZA Normalized: evkeeza |
Biological | Regeneron Healthcare Solutions, Inc. | $18.72 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $18.24 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $15.71 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $15.46 | 1 | 2025 |
Source payment records
|
|||||
| GIMOTI Normalized: gimoti |
Drug | EVOKE PHARMA, INC. | $15.02 | 1 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $14.72 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.44 | 1 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $14.03 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 102 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
126 | 36 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
102 | 19 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
102 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
61 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 539 | 157 |
| Amlodipine Besylate | Amlodipine Besylate | 519 | 153 |
| Lisinopril | Lisinopril | 466 | 136 |
| Atorvastatin Calcium | Atorvastatin Calcium | 379 | 121 |
| Omeprazole | Omeprazole | 325 | 98 |
| Hydrochlorothiazide | Hydrochlorothiazide | 309 | 100 |
| Montelukast Sodium | Montelukast Sodium | 267 | 75 |
| Allopurinol | Allopurinol | 262 | 78 |
| Metformin Hcl | Metformin Hcl | 246 | 73 |
| Losartan Potassium | Losartan Potassium | 240 | 77 |
| Carvedilol | Carvedilol | 238 | 67 |
| Metoprolol Succinate | Metoprolol Succinate | 222 | 66 |
| Pantoprazole Sodium | Pantoprazole Sodium | 181 | 52 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 160 | 49 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 152 | 51 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 148 | 48 |
| Eliquis | Apixaban | 141 | 35 |
| Tamsulosin Hcl | Tamsulosin Hcl | 135 | 39 |
| Clopidogrel | Clopidogrel Bisulfate | 134 | 38 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 129 | 95 |
| Synthroid | Levothyroxine Sodium | 126 | 36 |
| Famotidine | Famotidine | 123 | 44 |
| Fluticasone Propionate | Fluticasone Propionate | 122 | 42 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 115 | 36 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 114 | 37 |
| Potassium Chloride | Potassium Chloride | 114 | 32 |
| Simvastatin | Simvastatin | 113 | 29 |
| Doxycycline Hyclate | Doxycycline Hyclate | 107 | 71 |
| Metoprolol Tartrate | Metoprolol Tartrate | 103 | 31 |
| Jardiance | Empagliflozin | 102 | 19 |
| Furosemide | Furosemide | 99 | 35 |
| Trazodone Hcl | Trazodone Hcl | 97 | 25 |
| Sertraline Hcl | Sertraline Hcl | 95 | 27 |
| Clonidine Hcl | Clonidine Hcl | 91 | 21 |
| Ezetimibe | Ezetimibe | 85 | 27 |
| Pravastatin Sodium | Pravastatin Sodium | 83 | 25 |
| Escitalopram Oxalate | Escitalopram Oxalate | 82 | 24 |
| Ropinirole Hcl | Ropinirole Hcl | 81 | 18 |
| Glimepiride | Glimepiride | 75 | 17 |
| Lovastatin | Lovastatin | 75 | 23 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 70 | 24 |
| Citalopram Hbr | Citalopram Hydrobromide | 67 | 24 |
| Glipizide | Glipizide | 65 | 21 |
| Tramadol Hcl | Tramadol Hcl | 65 | 14 |
| Febuxostat | Febuxostat | 64 | 22 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 63 | 14 |
| Rybelsus | Semaglutide | 61 | 15 |
| Doxazosin Mesylate | Doxazosin Mesylate | 52 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 50 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 48 | 15 |
| Meloxicam | Meloxicam | 48 | 19 |
| Tizanidine Hcl | Tizanidine Hcl | 47 | 14 |
| Ondansetron Odt | Ondansetron | 45 | 14 |
| Azelastine Hcl | Azelastine Hcl | 44 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 44 | 15 |
| Metformin Hcl Er | Metformin Hcl | 44 | 17 |
| Breo Ellipta | Fluticasone/Vilanterol | 43 | 11 |
| Atenolol | Atenolol | 40 | 12 |
| Colestipol Hcl | Colestipol Hcl | 39 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 39 | 15 |
| Spironolactone | Spironolactone | 37 | 16 |
| Gabapentin | Gabapentin | 36 | suppressed |
| Glipizide Er | Glipizide | 35 | suppressed |
| Finasteride | Finasteride | 34 | 13 |
| Nifedipine Er | Nifedipine | 33 | suppressed |
| Januvia | Sitagliptin Phosphate | 32 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 32 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 31 | 12 |
| Bupropion Hcl Sr | Bupropion Hcl | 31 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 31 | 14 |
| Donepezil Hcl | Donepezil Hcl | 30 | 12 |
| Fluconazole | Fluconazole | 30 | 21 |
| Quetiapine Fumarate | Quetiapine Fumarate | 30 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 29 | suppressed |
| Irbesartan | Irbesartan | 29 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 29 | suppressed |
| Mirtazapine | Mirtazapine | 29 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 28 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 28 | suppressed |
| Trulicity | Dulaglutide | 28 | suppressed |
| Valsartan | Valsartan | 28 | 11 |
| Azithromycin | Azithromycin | 27 | 21 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 27 | suppressed |
| Ozempic | Semaglutide | 27 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 25 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 25 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 24 | suppressed |
| Prednisone | Prednisone | 24 | suppressed |
| Methylprednisolone | Methylprednisolone | 22 | 13 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 22 | suppressed |
| Ramipril | Ramipril | 22 | suppressed |
| Repatha Sureclick | Evolocumab | 22 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 21 | 15 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Xarelto | Rivaroxaban | 21 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 20 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 19 | suppressed |
| Linzess | Linaclotide | 19 | suppressed |
| Nitroglycerin | Nitroglycerin | 19 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Acyclovir | Acyclovir | 18 | suppressed |
| Baclofen | Baclofen | 18 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Lansoprazole | Lansoprazole | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 18 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 18 | 11 |
| Ssd | Silver Sulfadiazine | 18 | 15 |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 18 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 17 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 17 | suppressed |
| Bupropion Xl | Bupropion Hcl | 17 | suppressed |
| Chlorthalidone | Chlorthalidone | 17 | suppressed |
| Estradiol | Estradiol | 17 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Telmisartan | Telmisartan | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | 13 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Nystatin | Nystatin | 16 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 16 | suppressed |
| Celecoxib | Celecoxib | 15 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 15 | suppressed |
| Clonazepam | Clonazepam | 14 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 14 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 14 | suppressed |
| Entresto | Sacubitril/Valsartan | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | suppressed |
| Myrbetriq | Mirabegron | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Cilostazol | Cilostazol | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Ibuprofen | Ibuprofen | 12 | suppressed |
| Pentoxifylline | Pentoxifylline | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Wellbutrin Xl | Bupropion Hcl | 12 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
| Lidocaine | Lidocaine | 11 | suppressed |
| Memantine Hcl | Memantine Hcl | 11 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 11 | suppressed |
| Repatha Syringe | Evolocumab | 11 | suppressed |
| Torsemide | Torsemide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $817.33 · 52 records | Lilly USA, LLC | Auvelity, CAPLYTA, Cologuard Collection Kit, Dexcom G6 Transmitter, EVKEEZA, FARXIGA, GIMOTI, Haegarda, Heplisav-B, JARDIANCE, Kerendia, MINIMED 780G, MOUNJARO, OTEZLA, Ozempic, REPATHA, SPRAVATO, TRELEGY ELLIPTA, VOQUEZNA, VRAYLAR, Veozah, Wegovy, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error